natgillin/translations-raw huggingface dataset:
All dogs received behavioural therapy and were treated either with Reconcile or with clomipramine (another medicine used to treat dogs with separation-related disorders). 
Vsi psi so prejemali vedenjsko terapijo in bodisi zdravilo Reconcile ali klomipramin (drugo vrsto zdravila, ki se uporablja za zdravljenje psov z vedenjskimi težavami, povezanimi z ločitvijo).
A field study was conducted in a large number of dogs that were treated for separation anxiety in two European countries. 
V dveh evropskih državah je bila opravljena terenska študija z velikim številom psov, ki so bili zdravljeni zaradi anksioznosti, povezane z ločitvijo.
Reconcile is a veterinary medicine used as an aid to treat dogs with behavioural problems caused by separation from their owners or homes or from other dogs (separation anxiety). 
Reconcile je zdravilo za uporabo v veterinarski medicini, ki se uporablja kot dodatek pri zdravljenju psov z vedenjskimi težavami, nastalimi zaradi ločitve od lastnika, doma ali drugih psov.
How is Reconcile used? 
Kako se zdravilo Reconcile uporablja?
It contains the active substance fluoxetine. 
Vsebuje zdravilno učinkovino fluoksetin.
For practical information about using Reconcile, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za praktične informacije o uporabi zdravila Reconcile naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For more information about treatment with Reconcile, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za več informacij o zdravljenju z zdravilom Reconcile naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
The tablets are given once a day. 
Izbrana jakost tablete je odvisna od telesne mase psa. Tablete se dajejo enkrat na dan.
How does Reconcile work? 
Kako zdravilo Reconcile deluje?
The main measure of effectiveness was based on improvements in any of these four symptoms during the first 24 weeks of treatment. 
Glavno merilo učinkovitosti je temeljilo na izboljšanju katerega koli izmed teh simptomov v prvih 24 tednih zdravljenja.
The company requested a re-examination of the initial opinion. 
Družba je zahtevala ponovno preučitev prvotnega mnenja.
those involved in stimulating the cells to grow and divide. 
tistimi, ki sodelujejo pri stimulaciji rasti in delitve celic.
In addition, major changes were made to the study design while the study was ongoing, which made the results difficult to interpret. 
Poleg tega so v času izvajanja študije precej spremenili zasnovo študije, zato je rezultate težko razlagati.
The CHMP refusal was confirmed after re-examination. 
Zavrnitev odbora CHMP je bila po ponovnem pregledu potrjena.
The CHMP was concerned about the reliability of the study results because a routine GCP (good clinical practice) inspection at the study sites revealed serious failings in the way the study had been conducted. 
Odbor CHMP je imel zadržke glede zanesljivosti rezultatov študije, saj je rutinski inšpekcijski pregled dobre klinične prakse na lokacijah klinične študije pokazal resne pomanjkljivosti v načinu izvedbe študije.
After considering the grounds for this request, the CHMP re-examined the opinion, and confirmed the refusal of the marketing authorisation on 14 September 2017. 
Po proučitvi razlogov za to zahtevo je odbor CHMP ponovno pregledal mnenje in dne 14. septembra 2017 potrdil zavrnitev vloge za dovoljenje za promet.
Refusal of the marketing authorisation for Masipro (masitinib) EMA/599464/2017 
Zavrnitev vloge za dovoljenje za promet z zdravilom Masipro (masitinib) EMA/599464/2017
By blocking these enzymes, Masipro is thought to help slow down the growth of the mast cells. 
Z zaviranjem teh encimov naj bi zdravilo Masipro pomagalo upočasniti rast mastocitov.
This means that it blocks enzymes known as tyrosine kinases, which can be found in some receptors in mast cells including 
To pomeni, da zavira encime, znane kot tirozin-kinaze, ki se nahajajo v nekaterih receptorjih na mastocitih, vključno s
The applicant presented data from a main study involving 135 patients with systemic mastocytosis who had severe symptoms including at least one of the following four: itching, hot flushes, depression and tiredness. 
Predlagatelj je predložil podatke glavne študije, ki je vključevala 135 bolnikov s sistemsko mastocitozo, ki so imeli hude simptome, vključno z vsaj enim izmed naslednjih štirih: srbenje, vročinski oblivi, depresija in utrujenost.
Finally, data on the safety of the medicine were limited and there were concerns regarding the medicine's side effects, including neutropenia (low levels of white blood cells) and harmful effects on the skin and liver, which were of relevance particularly because the medicine was to be used long term. 
Tudi podatki o varnosti zdravila so bili omejeni in obstajali so pomisleki o neželenih učinkih zdravila, vključno z nevtropenijo (nizkim številom belih krvnih celic) in škodljivimi učinki na kožo in jetra, kar je bilo pomembno predvsem zato, ker naj bi se zdravilo uporabljalo dolgoročno.
Masipro was expected to be used to treat adults with systemic mastocytosis, a disease in which there are too many mast cells (a type of white blood cell) in the skin, bones and various body organs, causing symptoms such as itchy skin, hot flushes, palpitations, fainting, bone pain, tiredness, vomiting, diarrhoea and depression. 
Zdravilo Masipro naj bi se uporabljalo za zdravljenje odraslih s sistemsko mastocitozo, boleznijo, pri katerih je v koži, kosteh in različnih telesnih organih preveč mastocitov (vrste belih krvnih celic), ki povzročajo simptome, kot so srbeča koža, navali vročine, palpitacije, omedlevica, bolečine v kosteh, utrujenost, bruhanje, driska in depresija.
How does Masipro work? 
Kako zdravilo Masipro deluje?
Refusal of the marketing authorisation for Masipro (masitinib) 
Zavrnitev vloge za dovoljenje za promet z zdravilom Masipro (masitinib)
On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Masipro, intended for the treatment of systemic mastocytosis. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je v svojem negativnem mnenju z dne 18. maja 2017 priporočil zavrnitev vloge za dovoljenje za promet z zdravilom Masipro, namenjenim zdravljenju sistemske mastocitoze.
What was Masipro expected to be used for? 
Za kaj naj bi se zdravilo Masipro uporabljalo?
In the study, Masipro was compared with placebo (a dummy treatment). 
V študiji so zdravilo Masipro primerjali s placebom (zdravilom brez zdravilne učinkovine).
Masipro was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 16 November 2004 for mastocytosis. 
Zdravilo Masipro je bilo dne 16. novembra 2004 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni) za zdravljenje mastocitoze.
Therefore, the CHMP was of the opinion that the benefits of Masipro did not outweigh its risks and recommended that it be refused marketing authorisation. 
Posledično je odbor CHMP tedaj menil, da koristi zdravila Masipro ne odtehtajo z njim povezanih tveganj, in priporočil, da se dovoljenje za promet z njim zavrne.
Masipro is a medicine that contains the active substance masitinib. 
Masipro je zdravilo, ki vsebuje zdravilno učinkovino masitinib.
The company informed the CHMP that there are no consequences for patients in clinical trials or compassionate use programmes. 
Družba je obvestila odbor CHMP, da zavrnitev nima posledic za bolnike, ki so vključeni v klinična preizkušanja ali programe sočutne uporabe.
The active substance in Masipro, masitinib, is a tyrosine kinase inhibitor. 
Zdravilna učinkovina v zdravilu Masipro, masitinib, je zaviralec tirozin-kinaze.
The company that applied for authorisation is AB Science. 
Vlogo za pridobitev dovoljenja za promet z zdravilom je predložila družba AB Science.
What is Masipro? 
Kaj je zdravilo Masipro?
A/equine-2/South Africa/4/03 strain 50 AU/ml A/equine-2/Newmarket/2/93 strain 
A/konjski-2/Južna Afrika/4/03 50 AU/ml A/konjski-2/ Newmarket/2/93 50 AU/ml
Horse Intramuscular use Vial (type I glass) closed with a halogenobutyl rubber stopper and aluminium cap. 
Intramuskularno Viala (steklo tipa I) zaprta z zamaškom iz halogenobutilne gume in aluminijasto zaporko
--1 Equine influenza virus strains: 
--1 Seva virusa influence konj:
MA (EU) number Invented name 
EU številka Izmišljeno ime Jakost Farmacevtska oblika
1 dose 10 glass vials 
1 odmerek 10 steklenih vi Nič dni
1 dose 1 pre-filled syringe 
1 odmerek 1 napolnjena brizga
They involved over 5,000 people from 4 years of age. 
Vključevali sta 5 000 ljudi, starejših od štirih let.
Further information on Flucelvax Tetra can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Flucelvax-tetra 
Nadaljnje informacije o zdravilu Flucelvax Tetra so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Flucelvax-tetra
Each year, the World Health Organization (WHO) makes recommendations on which flu strains should be included in vaccines for the upcoming flu season in the northern hemisphere. 
Svetovna zdravstvena organizacija (SZO) vsako leto pripravi priporočila o tem, kateri sevi gripe naj se vključijo v cepiva za naslednjo sezono gripe na severni polobli.
The recommended dose is one single injection into a muscle (0.5 ml), preferably in the upper arm. 
Priporočeni odmerek je enkratna injekcija v mišico (0,5 ml), po možnosti v nadlaket.
The European Medicines Agency therefore decided that Flucelvax Tetra's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Flucelvax Tetra večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
The composition of Flucelvax Tetra will be updated annually according to WHO and EU recommendations. 
Sestava cepiva Flucelvax Tetra bo vsako leto posodobljena v skladu s priporočili organizacije Svetovne zdravstvene organizacije in Evropske unije.
The studies assessed the ability of the vaccines to stimulate an immune response against influenza, by measuring the production of protective antibodies. 
V študijah so ocenili sposobnost cepiv za sprožanje imunskega odziva proti gripi, tako da so merili tvorbo zaščitnih protiteles.
The most common side effects with Flucelvax Tetra (which may affect more than 1 in 10 people) are pain at the injection site, reddening of the skin and hardening at the injection site, headache, tiredness and muscle pain. 
Najpogostejši neželeni učinki zdravila Flucelvax Tetra (ki lahko prizadenejo več kot 1 osebo od 10) so bolečina, pordelost in otrdelost kože na mestu injiciranja, glavobol, utrujenost in bolečine v mišicah.
What measures are being taken to ensure the safe and effective use of Flucelvax Tetra? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Flucelvax Tetra?
Side effects reported with Flucelvax Tetra are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Flucelvax Tetra, se skrbno ovrednotijo in po potrebi sprejmejo ukrepi za zaščito bolnikov.
The immune system will then be able to respond more quickly when it is exposed to the virus again. 
Ob ponovni izpostavitvi virusom se bo imunski sistem lahko hitreje odzval nanje.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Flucelvax Tetra have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Flucelvax Tetra upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
For more information about using Flucelvax Tetra, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Flucelvax Tetra glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
As for all medicines, data on the use of Flucelvax Tetra are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Flucelvax Tetra stalno spremljajo.
Flucelvax Tetra was compared with two comparator vaccines in 2 main studies. 
Zdravilo Flucelvax Tetra so primerjali z dvema primerjalnima cepivoma v dveh glavnih študijah.
Flucelvax Tetra is a vaccine used to protect adults and children from 9 years of age against influenza (flu). 
Zdravilo Flucelvax Tetra je cepivo, ki se uporablja za zaščito odraslih in otrok od 9. leta starosti proti influenci (gripi).
The inclusion of two influenza B strains in Flucelvax Tetra can provide a broader protection against influenza B. In terms of safety, side effects with Flucelvax Tetra are similar to those observed with vaccines containing three influenza strains and are mostly mild to moderate in severity. 
Vključitev dveh sevov gripe B v zdravilo Flucelvax Tetra lahko zagotovi večjo zaščito proti gripi B. Z vidika varnosti so neželeni učinki zdravila Flucelvax Tetra podobni tistim, opaženim pri cepivih, ki vsebujejo tri seve virusa gripe in so večinoma blagi ali zmerni.
Flucelvax Tetra contains proteins from four different inactivated influenza A and B virus strains (type A-H1N1, type A-H3N2 and two type B strains), chosen based on the official recommendation for the annual flu season. 
Zdravilo Flucelvax Tetra vsebuje beljakovine iz štirih različnih inaktiviranih sevov virusa gripe A in B (tip A-H1N1, tip A-H3N2 in dva seva virusa gripe B) na podlagi uradnega priporočila za vsakoletno sezono gripe.
Influenza is mainly caused by two kinds of influenza virus, known as influenza A and B. Each of these circulate as different strains and subtypes, which change over time. 
Gripo običajno povzročata dve vrsti virusa, tj. virus gripe A in virus gripe B. Vsak od njiju kroži v obliki različnih sevov in podtipov, ki se sčasoma spreminjajo.
Results showed that Flucelvax Tetra lead to similar levels of protective antibodies as the comparator vaccines in people from 9 years of age. 
Rezultati so pokazali, da zdravilo Flucelvax Tetra doseže podobne zaščitne ravni protiteles kot primerjalna cepiva pri ljudeh, starejših od devetih let.
Other information about Flucelvax Tetra 
Druge informacije o zdravilu Flucelvax Tetra
An overview of Flucelvax Tetra and why it is authorised in the EU 
Pregled zdravila Flucelvax Tetra in zakaj je odobreno v EU
Flucelvax Tetra is available as a suspension for injection in a pre-filled syringe. 
Zdravilo Flucelvax Tetra je na voljo kot suspenzija za injiciranje v napolnjeni injekcijski brizgi.
The vaccine can only be obtained with a prescription and should be used according to official recommendations. 
Predpisovanje in izdaja zdravila Flucelvax Tetra je le na recept, uporabljati pa se mora v skladu z uradnimi priporočili.
Why is Flucelvax Tetra authorised in the EU? 
Zakaj je bilo zdravilo Flucelvax Tetra odobreno v EU?
The other vaccine is based on Optaflu but contains the other B strain of Flucelvax Tetra. 
Drugo cepivo temelji na zdravilu Optaflu, a vsebuje drugi sev B, ki se nahaja v zdravilu Flucelvax Tetra.
When a person is given the vaccine, the immune system recognises the virus proteins as ‘foreign' and makes defences against them. 
Ko oseba prejme cepivo, imunski sistem prepozna delce virusa kot tujke in proti njim razvije protitelesa.
One of the vaccines was Optaflu, a previously authorised vaccine which contains three of the four strains of influenza in Flucelvax Tetra and whose effectiveness in preventing flu is well established. 
Eno izmed teh cepiv je bilo zdravilo Optaflu, ki je bilo predhodno odobreno cepivo in vsebuje tri od štirih sevov gripe, ki se nahajajo v zdravilu Flucelvax Tetra in katerih učinkovitost je bila že dokazana.
Flucelvax Tetra is as effective as the comparator vaccines at stimulating immune responses against the 4 strains included in the vaccine in people from 9 years of age. 
Zdravilo Flucelvax Tetra je enako učinkovito kot primerjalna cepiva pri spodbujanju imunskega odziva proti 4 sevom, vključenim v cepivo pri osebah, starejših od devet let.
Flucelvax Tetra is a vaccine. 
Zdravilo Flucelvax Tetra je cepivo.
For the full list of side effects and restrictions with Flucelvax Tetra, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Flucelvax Tetra glejte navodilo za uporabo.
What is Flucelvax Tetra and what is it used for? 
Kaj je zdravilo Flucelvax Tetra in za kaj se uporablja?
What benefits of Flucelvax Tetra have been shown in studies? 
Kakšne koristi je zdravilo Flucelvax Tetra izkazalo v študijah?
The viruses used to produce Flucelvax Tetra are grown in mammalian cells. 
Virusi, ki se uporabljajo v cepivu , so vzgojeni v celicah sesalcev.
What are the risks associated with Flucelvax Tetra? 
Kakšna tveganja so povezana z zdravilom Flucelvax Tetra?
Historically, seasonal flu vaccines have contained three strains of flu: one influenza A-H1N1 virus, one influenza AH3N2 virus, and one influenza B virus. 
V preteklosti so cepiva proti gripi vsebovala tri seve virusa gripe: en virus gripe A-H1N1, en virus gripe AH3N2 in en virus gripe B. Zdravilo Flucelvax Tetra vsebuje dodaten sev virusa gripe B.
Flucelvax Tetra contains proteins from the surface of four different strains of flu virus. 
Zdravilo Flucelvax Tetra vsebuje delce s površine štirih različnih sevov virusa gripe.
Together the comparator vaccines contain the four strains of influenza in Flucelvax Tetra. 
Primerjalni cepivi skupaj vsebujeta vse štiri seve, ki se nahajajo v zdravilu Flucelvax Tetra.
How is Flucelvax Tetra used? 
Kako se zdravilo Flucelvax Tetra uporablja?
How does Flucelvax Tetra work? 
Kako zdravilo Flucelvax Tetra deluje?
Flucelvax Tetra includes an additional B virus strain. 
Flucelvax Tetra (cepivo proti gripi [površinski antigen,
What measures are being taken to ensure the safe and effective use of Liprolog? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Liprolog?
Liprolog Mix is a mixture of these two formulations. 
Liprolog Mix je mešanica teh dveh pripravkov.
The full EPAR for Liprolog can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Liprolog je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Liprolog on 1 August 2001. 
Evropska komisija je dovoljenje za promet z zdravilom Liprolog, veljavno po vsej Evropski uniji, izdala dne 1. avgusta 2001.
Patients can inject themselves with this medicine if they have been trained appropriately. 
Bolniki si lahko zdravilo Liprolog vbrizgajo sami, če so bili za to ustrezno usposobljeni.
This is a summary of the European public assessment report (EPAR) for Liprolog. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Liprolog.
• Liprolog: insulin lispro solution, available in a standard or a higher strength (100 or 200 units/ml); 
• Liprolog: raztopina insulina lispro, na voljo v standardni ali višji jakosti (100 ali 200 enot/ml);
For more information about treatment with Liprolog, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Liprolog preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Other information about Liprolog 
Druge informacije o zdravilu Liprolog
Liprolog and Liprolog Mix are normally given shortly before a meal, but they can be given just after a meal if necessary. 
Zdravili Liprolog in Liprolog Mix se običajno dajeta tik pred obrokom, po potrebi pa se lahko jemljeta tudi kmalu po obroku.
Studies also looked at the use of Liprolog in 542 patients aged between two and 19 years, and the use of Liprolog in combination with sulphonylureas. 
V študijah so proučevali tudi uporabo zdravila Liprolog pri 542 bolnikih, starih od dve do 19 let, in uporabo zdravila Liprolog v kombinaciji s sulfonilsečninami.
What is the risk associated with Liprolog? 
Kakšna tveganja so povezana z zdravilom Liprolog?
Insulin lispro is very slightly different from human insulin. 
Insulin lispro se zelo malo razlikuje od humanega insulina.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Liprolog. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What benefit has Liprolog shown during the studies? 
Kakšne koristi je zdravilo Liprolog izkazalo med študijami?
In addition, the company that makes Liprolog has provided information to patients and healthcare professionals to remind them that there are two strengths of Liprolog and to advise them on how to use them safely to avoid medication errors. 
Poleg tega je družba, ki izdeluje zdravilo Liprolog, bolnikom in zdravstvenim delavcem zagotovila informacije, ki jih opominjajo, da obstajata dve jakosti zdravila Liprolog in nasvete o tem, kako ju varno uporabljati v izogib napačni uporabi.
The difference means that insulin lispro is absorbed faster by the body than human regular insulin, and can therefore act faster. 
Razlika je v tem, da človeško telo insulin lispro absorbira hitreje kot običajni humani insulin, zaradi česar lahko hitreje učinkuje.
A risk management plan has been developed to ensure that Liprolog is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Liprolog je bil pripravljen načrt obvladovanja tveganj.
Liprolog is a range of solutions and suspensions for injection. 
Zdravilo Liprolog je serija raztopin in suspenzij za injiciranje.
LiprologLiprolog doses might need to be adjusted when given with other medicines that may have an effect on blood glucose levels. 
Odmerke zdravila Liprolog bo morda treba prilagoditi, če se jemlje sočasno z nekaterimi drugimi zdravili, ki bi lahko vplivala na raven glukoze v krvi.
Liprolog was originally studied in eight clinical trials including 2951 patients with type 1 diabetes (when the body cannot produce insulin) or type 2 diabetes (when the body is unable to use insulin effectively). 
Zdravilo Liprolog so najprej proučevali v okviru osmih kliničnih študij z 2 951 bolniki s sladkorno boleznijo tipa 1 (pri kateri trebušna slinavka ne more tvoriti insulina) ali sladkorno boleznijo tipa 2 (pri kateri telo insulina ne more učinkovito izrabljati).
The Committee recommended that Liprolog be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Liprolog izda dovoljenje za promet.
The active substance in Liprolog, insulin lispro, is produced by a method known as ‘recombinant DNA technology': it is made by bacteria into which a gene (DNA) has been introduced, which makes them able to produce insulin lispro. 
Zdravilno učinkovino v zdravilu Liprolog, insulin lispro, proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri se v bakterijo vstavi gen (DNK), s katerim lahko tvori insulin lispro.
Diabetes is a disease in which the body does not produce enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. 
Sladkorna bolezen je bolezen, pri kateri telo ne proizvaja dovolj insulina za vzdrževanje primerne koncentracije glukoze v krvi ali pri kateri telo ne more insulina učinkovito uporabljati.
Liprolog may cause hypoglycaemia (low blood glucose levels) and must not be given to patients whose blood glucose is already low. 
Zdravilo Liprolog lahko povzroči hipoglikemijo (nizko raven glukoze v krvi) in se ne sme dajati bolnikom, katerih raven glukoze v krvi je že tako nizka.